Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection: A Randomized Controlled Trial
Tanta University
320 participants
Sep 11, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.
Eligibility
Inclusion Criteria4
- Adults aged ≥18 years.
- Both sexes.
- Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).
- No prior eradication therapy.
Exclusion Criteria6
- Prior Helicobacter pylori treatment.
- Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.
- Gastric surgery history.
- Major organ failure.
- Pregnancy or lactation.
- Known allergy to study drugs.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.
Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07165444